Clinical Trial Update: 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen [Phase 2]

View source ↗

Summary

Phase 2 trial completed evaluating gemcitabine monotherapy as second-line treatment for urothelial carcinoma after cisplatin-based therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Gemzar (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Urologic Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Status: COMPLETED